Advancing HFpEF Treatment with Novel MRAs

Panelists discuss how evolving diagnostic precision, evidence-based MRA use, and combination therapy strategies are transforming HFpEF care while addressing real-world challenges in access and adherence.

Experts highlight the importance of precise diagnostic criteria and multimodal assessments to distinguish HFpEF from overlapping cardiovascular conditions.

The discussion centers on proactive screening and early intervention approaches to improve outcomes and slow HFpEF progression.

Panelists emphasize strategies to enhance patient quality of life and reduce hospital readmissions through optimized therapeutic management.

Experts examine how updated guidelines are influencing the integration of novel MRAs and other agents into HFpEF treatment algorithms.

The conversation compares the efficacy and safety of nonsteroidal and steroidal MRAs, focusing on clinical decision-making and patient selection.

Panelists explore the mechanistic benefits of aldosterone antagonism and its evolving role within HFpEF therapeutic frameworks.

The group reviews key findings from FINEARTS-HF and discusses how finerenone’s approval expands treatment options for patients with HFpEF.

Experts discuss the clinical implications of finerenone’s benefits and forecast how upcoming guidelines may shift standard care practices.

The panel focuses on balancing efficacy and safety when choosing MRAs for patients with HFpEF with complex comorbid conditions such as CKD and diabetes.

Panelists share insights on how best to sequence MRAs, SGLT2 inhibitors, and ARNis to maximize patient outcomes and adherence.

Discussion centers on combining MRAs with other agents while maintaining vigilant monitoring to minimize risks and optimize long-term management.

Experts highlight preventive approaches, including risk factor control and early therapeutic intervention, to mitigate HFpEF development.

Panelists address adherence challenges and the need for careful coordination when integrating nonsteroidal MRAs into multifaceted treatment plans.

The discussion concludes with strategies to overcome access barriers and ensure equitable implementation of novel HFpEF therapies.